The FDA has approved canadian ziprasidone (Geodon, Pfizer) to treat acute bipolar mania. Nearly 4% of Americans have bipolar disorder, a condition that causes severe mood swings. Rapid control of acute mania is important, because patients are at increased risk for dangerous and impulsive acts, including aggressive and suicidal behavior.
This product causes little or no weight gain and is associated with fewer adverse changes in certain metabolic indices, such as lipid levels and glucose control, than other agents in its class. Significant improvements were typically seen within two days after treatment began.
According to a survey conducted by Harris Interactive® of 554 patients with bipolar disorder in the U.S. over the age of 30, most patients gained an average of 50 pounds while taking other bipolar drugs; 10% gained 100 pounds or more with other drugs.
Geodon medication was approved for the treatment of schizophrenia in the U.S. in February 2001 and received approval for treating acute bipolar mania in August 2004.